Loading
A phase 2 trial of Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events is a phase 2 interventional study registered as NCT06500884 by Janssen Research & Development, LLC, with 210 participants planned, started 2024-08-26 and due to reach its primary completion in 2030-05-30. Interventions recorded: Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/